Annual report pursuant to Section 13 and 15(d)

Shareholders??? Equity (Tables)

v3.24.1
Shareholders’ Equity (Tables)
12 Months Ended
Dec. 31, 2023
Shareholders’ Equity [Abstract]  
Schedule of Awards Granted During the years ended December 31, 2023, and December 2022, the following awards were granted:
Award Type (2015 Plan)   Number of
Awards in
2023
    Number of
Awards in
2022 (*)
    Vesting Conditions   Expiration Date
Options     400       16,778     Over 4 years from grant date-25% every year (from the second year- 2.08% each month)   10th anniversary of Grant Date
RSU     45,100       59,200     Over 3 years from grant date    
* Adjusted to reflect reverse stock split, see note 2(ff).
Schedule of Share Option Activity Under Option Plans A summary of the Company’s share option activity under option plans is as follows:
    Number of
Options
    Weighted-
Average
Exercise
Price
    Weighted
Average
Remaining
Contractual
Life
 
Outstanding – January 1, 2023     96,459     $ 4.89       5.34  
Granted     400     $ 1.48       9.71  
Exercised     (2,489 )   $ 0.90          
Forfeited     (6,606 )   $ 22.74          
                         
Outstanding – December 31, 2023     87,764     $ 3.63       4.11  
                         
Exercisable – December 31, 2023     80,064     $ 2.36       3.67  
    Number of
Options (*)
    Weighted-
Average
Exercise
Price (*)
    Weighted
Average
Remaining
Contractual
Life
 
Outstanding – January 1, 2022     89,049     $ 1.52       5.43  
Granted     16,778     $ 21.96          
Exercised     (7,775 )   $ 0.81          
Forfeited     (1,593 )   $ 15.09          
                         
Outstanding – December 31, 2022     96,459     $ 4.89       5.34  
                         
Exercisable – December 31, 2022     77,196     $ 1.48       4.36  
* Adjusted to reflect reverse stock split, see note 2(ff).
Schedule of Ordinary Shares Issuable upon Outstanding Options and Exercisable Options The following table summarize information as of December 31, 2023, regarding the number of ordinary shares issuable upon outstanding options and exercisable options:
Exercise price   Options
outstanding as of
December 31,
2023
    Weighted
average
remaining
contractual
life (years)
    Options
exercisable as of
December 31,
2023
    Weighted
average
remaining
contractual
life (years)
 
0.64     30,309       1.61       30,309       1.61  
1.06     43,461       4.44       43,402       4.43  
1.48     400       9.71       100       9.71  
5.78     5,500       8.96       1,750       8.96  
13.62     3,894       7.41       2,524       7.41  
40.00     4,200       8.72       1,979       8.72  
      87,764               80,064          
Exercise price   Options
outstanding as of
December 31,
2022 (*)
    Weighted
average
remaining
contractual
life (years)
    Options
exercisable as of
December 31,
2022
    Weighted
average
remaining
contractual
life (years)
 
0.64     31,236       2.61       31,236       2.61  
1.06     44,989       5.43       43,752       5.39  
5.78     8,843       9.96      
-
     
-
 
13.62     3,891       8.41       1,547       8.41  
40.00     7,500       9.72       661       9.72  
      96,459               77,196          
* Adjusted to reflect reverse stock split, see note 2(ff).
Schedule of Fair Value of the Share Options Granted

Key assumptions used to estimate the fair value of the share options granted during the year ended December 31, 2022 included:

       
    2022  
Expected term of options (years)     10  
Expected common stock price volatility**    
54
%
Expected dividend rate     0 %
Risk-free interest rate     3.21%-3.25 %
** The expected volatility was based on the historical stock prices of publicly traded comparable companies.

 

Schedule of Share-Based Compensation Expense for Share Options Share-based compensation expense for share options in the consolidated statements of comprehensive loss is summarized as follows:
    Year Ended
December 31,
 
    2023     2022  
Cost of revenues     3       3  
Research and development     23       26  
Sales and marketing     11       11  
General and administrative     11       12  
Total Share-based compensation expense     48       52  
Share-based compensation expense for RSUs in the consolidated statement of comprehensive loss is summarized as follows:
    Year Ended
December 31
 
    2023     2022  
    U.S. dollars in thousands  
Cost of revenues     9       3  
Research and development     53       18  
Sales and marketing     47       12  
General and administrative     220       135  
Total Share-based compensation expense     329       168  
Schedule of RSUs Activity under Option Plans A summary of the Company’s RSUs activity under option plans is as follows:
    Year ended
December 31, 2023
    Year ended
December 31, 2022
 
    Number of
RSUs
    Weighted-
Average Grant
Date Fair Value
    Number of
RSUs (*)
    Weighted-
Average Grant
Date Fair Value
 
RSUs outstanding at the beginning of the year     59,200     $ 16.20      
-
     
-
 
Granted during the year     43,100     $ 3.33       59,200     $ 16.20  
Vested during the year     (29,520 )     12.36      
-
     
-
 
Forfeited during the year     (1,500 )     16.20      
-
     
-
 
Outstanding at the end of the year     71,280     $ 10.35       59,200     $ 16.20  
* Adjusted to reflect reverse stock split, see note 2(ff).